Carcinoid Tumors
December 2022 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Does Examined Lymph Node Count Influence Survival in Surgically Resected Early‑stage Pulmonary Typical Carcinoid Tumors?
Authors:Yang H, Liu T, Li M, Fang Z, Luo L
Institution:Department of Internal Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital.
Journal:Am J Clin Oncol. 2022 Dec 1;45(12):506-513. doi: 10.1097/COC.0000000000000958. Epub 2022 Nov 15.

2:Patients with ectopic ACTH syndrome might have a better prognosis in bronchopulmonary carcinoids with lymph node metastasis received radical surgery: a single-centre retrospective study in the last 22 years in China.
Authors:Gao C, Zhang J, Wang Y, Huang C, Zhang Y, Chen Y, Li S
Institution:Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China. lishanqing@pumch.cn.
Journal:BMC Surg. 2022 Nov 8;22(1):383. doi: 10.1186/s12893-022-01831-5.

3:Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid.
Authors:Li S, Wang X, Sui X, Zhang X, Yin M, Yang J
Institution:National Clinical Research Center for Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China. yangjiaxin@pumch.cn.
Journal:BMC Cancer. 2022 Oct 24;22(1):1090. doi: 10.1186/s12885-022-10167-5.

4:Four decades of experience with carcinoid heart disease: An analysis of 84 patients.
Authors:Levy S, Korse CE, de Groot ACA, Meijer RCA, Tesselaar MET, Valk GD
Institution:Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Endocrine Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Journal:J Neuroendocrinol. 2022 Oct;34(10):e13199. doi: 10.1111/jne.13199. Epub 2022 Oct 18.

5:Clinical Spectrum and Endoscopic Treatment of Gastrointestinal Carcinoid Tumour.
Authors:Xue L, Cai Y, Chen W, Chen S, Xue P
Institution:Department of Gastrointestinal Surgery, The First Hospital of Putian Teaching Hospital, Fujian Medical University, Putian, Fujian, China.
Journal:J Coll Physicians Surg Pak. 2022 Oct;32(10):1330-1333. doi: 10.29271/jcpsp.2022.10.1330.

6:The occurrence and associated risk factors of brain metastases in well differentiated grade 1 and 2 bronchial neuroendocrine tumours: A single centre retrospective analysis of 280 patients.
Authors:Spurgeon L, Jones J, Lewis A, Rammohan K, Shaheen F, Weaver J, Papaxoinis G, Mansoor W
Institution:Diabetes and Endocrinology, Manchester Royal Infirmary, Manchester, UK.; Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Journal:J Neuroendocrinol. 2022 Jul;34(7):e13180. doi: 10.1111/jne.13180.

7:Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome.
Authors:Koumarianou A, Daskalakis K, Tsoli M, Kaltsas G, Pavel M
Institution:Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.; Department of Endocrinology, Universitatsklinikum Erlangen, Erlangen, Germany.
Journal:J Neuroendocrinol. 2022 Jul;34(7):e13174. doi: 10.1111/jne.13174. Epub 2022 Jul 6.

8:Carcinoid ovary with synchronous carcinoid tumour of the appendix: report of a rare occurrence with review of literature.
Authors:Baruah U, Tak A, Kakoti L, Barmon D
Institution:Gynaecologic Oncology, Dr B Borooah Cancer Society Trust, Guwahati, Assam, India.
Journal:BMJ Case Rep. 2022 Jun 24;15(6):e248869. doi: 10.1136/bcr-2022-248869.

9:Neuroendocrine neoplasms of the ovary: an analysis of clinicopathological characteristics and prognosis with a focus on histological grading.
Authors:Huang W, Bao Y, Luo X, Yao L, Yuan L
Institution:Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. yuanlei1529@163.com.
Journal:Endocrine. 2022 Jun;77(1):188-198. doi: 10.1007/s12020-022-03067-y. Epub 2022 May 11.

10:Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Authors:Kostiainen I, Karppinen N, Simonen P, Rosengård-Bärlund M, Lindén R, Tarkkanen M, Gordin D, Rapola J, Schalin-Jäntti C, Matikainen N
Institution:Endocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. niina.matikainen@hus.fi.
Journal:Endocrine. 2022 Jun;77(1):177-187. doi: 10.1007/s12020-022-03065-0. Epub 2022 May 10.

11:Lymphadenectomy for lung carcinoids: Which factors may predict nodal upstaging? A multi centric, retrospective study.
Authors:Chiappetta M, Lococo F, Sperduti I, Cusumano G, Terminella A, Fournel L, Guerrera F, Filosso P, Tabacco D, Nicosia S, Alifano M, Gallina F, Facciolo F, Margaritora S
Institution:Thoracic Surgery, Universita cattolica del Sacro Cuore, Rome, Italy.
Journal:J Surg Oncol. 2022 Sep;126(3):588-598. doi: 10.1002/jso.26912. Epub 2022 May 6.

12:Sublobar resection versus lobectomy for patients with stage T1-2N0M0 pulmonary typical carcinoid tumours: a population-based propensity score matching analysis.
Authors:Yang H, Mei T
Institution:Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
Journal:Interact Cardiovasc Thorac Surg. 2022 Aug 3;35(3):ivac125. doi: 10.1093/icvts/ivac125.

13:High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?
Authors:Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J
Institution:Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28034, Madrid, Spain. talonsogordoa@gmail.com.
Journal:Curr Treat Options Oncol. 2022 Jul;23(7):1001-1013. doi: 10.1007/s11864-022-00983-z. Epub 2022 May 1.

14:Sex-based differences in the outcomes of patients with lung carcinoids.
Authors:Abdel-Rahman O, Ghosh S, Fazio N
Institution:Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, Canada.; Department of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy.
Journal:J Comp Eff Res. 2022 May;11(7):523-531. doi: 10.2217/cer-2021-0205. Epub 2022 Apr 7.

15:Single utility port approach in robot-assisted sleeve segmentectomy for bronchial carcinoid tumor.
Authors:Liu A, Zhao Y, Qiu T, Xuan Y, Qin Y, Sun X, Xu R, Du W, Jiao W
Institution:Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Shandong, China.
Journal:Thorac Cancer. 2022 May;13(10):1537-1540. doi: 10.1111/1759-7714.14409. Epub 2022 Apr 6.

16:The prevalence, operations, and outcomes of carcinoid heart disease.
Authors:Macfie R, McCully BH, Ratzlaff AN, Lim J, Song HK, Dewey EN, Pommier SJ, Bhamidipati CM, Pommier RF
Institution:Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University, Portland, OR, USA. Electronic address: pommierr@ohsu.edu.
Journal:Am J Surg. 2022 Aug;224(2):665-669. doi: 10.1016/j.amjsurg.2022.03.054. Epub 2022 Mar 31.

17:Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study.
Authors:Yang H, Xiao X, Mei T, Zhou P
Institution:Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Youyi No 1 Road, Yuzhong, Chongqing, 400016, People's Republic of China.; Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Youyi No 1 Road, Yuzhong, Chongqing, 400016, People's Republic of China. pingzhou12345@163.com.
Journal:Aging Clin Exp Res. 2022 Aug;34(8):1925-1934. doi: 10.1007/s40520-022-02112-0. Epub 2022 Mar 28.

18:Anatomic Pulmonary Resection is Associated With Improved Survival in Typical Carcinoid Lung Tumor Patients.
Authors:Del Calvo H, Nguyen DT, Chan EY, Chihara R, Graviss EA, Kim MP
Institution:Division of Thoracic Surgery, Department of Surgery, Houston Methodist Hospital, Houston, Texas.; Division of Thoracic Surgery, Department of Surgery, Houston Methodist Hospital, Houston, Texas; Department of Surgery and Cardiothoracic Surgery, Weill Cornell Medical College, Houston Methodist Hospital, Houston, Texas. Electronic address: mpkim@houstonmethodist.org.
Journal:J Surg Res. 2022 Jul;275:352-360. doi: 10.1016/j.jss.2022.02.048. Epub 2022 Mar 24.

19:Sex differences in carcinoid syndrome: A gap to be closed.
Authors:Ruggeri RM, Altieri B, Grossrubatcher E, Minotta R, Tarsitano MG, Zamponi V, MIsidori A, Faggiano A, Colao AM
Institution:Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina, Italy. rmruggeri@unime.it.; Department of Clinical Medicine and Surgery, Endocrinology Unit, University Federico II, Naples, Italy.
Journal:Rev Endocr Metab Disord. 2022 Jun;23(3):659-669. doi: 10.1007/s11154-022-09719-8. Epub 2022 Mar 16.

20:Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.
Authors:Maxwell JE, Naraev B, Halperin DM, Choti MA, Halfdanarson TR
Institution:Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Halfdanarson.Thorvardur@mayo.edu.
Journal:Ann Surg Oncol. 2022 May;29(5):3072-3084. doi: 10.1245/s10434-022-11371-0. Epub 2022 Feb 14.

21:Recent Advances in the Diagnosis and Management of Carcinoid Syndrome.
Authors:Subash N, Papali MM, Bahadur KP, Avanthika C, Jhaveri S, Thannir S, Joshi M, Valisekka SS
Institution:Ramaiah Medical College, MSR Nagar, Mathikere, Bengaluru, Karnataka 560054, India.; Sri Venkateshwara Medical College, Alipiri Road, Tirupati, Andhra Pradesh 517501, India.
Journal:Dis Mon. 2022 Jul;68(7):101304. doi: 10.1016/j.disamonth.2021.101304. Epub 2021 Dec 28.

22:Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series.
Authors:Chan DL, Pavlakis N, Crumbaker M, Lawrence B, Barber C, Price TJ, Michael M, Oberg K
Institution:Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.; Department of Endocrine Oncology, University Hospital, Uppsala, Sweden.
Journal:Asia Pac J Clin Oncol. 2022 Jun;18(3):209-216. doi: 10.1111/ajco.13577. Epub 2021 Apr 14.

23:Sublobar Resection Versus Lobectomy for Early-Stage Pulmonary Carcinoid Tumors ≤3 cm in Size: A SEER Population-Based Study.
Authors:Xu S, Li X, Ren F, He J, Zhao S, Wang Y, Ren D, Zhu S, Lei X, Chen G, Chen J
Institution:Department of Lung Cancer Surgery.
Journal:Ann Surg. 2022 Dec 1;276(6):e991-e999. doi: 10.1097/SLA.0000000000004593. Epub 2020 Nov 13.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 20% Discount


Medifocus Guidebook on Carcinoid Tumors

Updated: January 10, 2023
166 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $37.45
  • Less 20% Discount = - $7.10
  • Discounted Price = $30.35(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $31.20
  • Less 20% Discount = - $6.45
  • Discounted Price = $24.75

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CT340997568

Coupon Expires: March 3, 2023



What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
P.T.
Newcastle, England


"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
F.B.
Nanaimo, British Columbia


"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
J.P.F.
Agoura Hills, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.